Search results for "enteric-coated mycophenolate sodium"

showing 3 items of 3 documents

Enteric-coated mycophenolate sodium in the treatment of refractory pemphigus.

2010

BACKGROUND: One of the major goals of pemphigus therapy is to reduce the patient's cumulative exposure to systemic corticosteroids. To investigate the efficacy of enteric-coated mycophenolate sodium (EC-MPS), 10 patients with active, refractory pemphigus vulgaris (PV) or foliaceous (PF) were treated with EC-MPS (1440 mg daily) and prednisone (75 mg daily) over 18 months. OBSERVATIONS: Following EC-MPS/prednisone therapy, disease progression was inhibited between days 30 and 45 in 9/10 patients (8 PV; 1 PF). At 18 months, 8/9 PV patients had clinically quiescent disease; EC-MPS therapy was no longer required in two patients as a result of disease remission. The remaining PV patient showed no…

AdultMaleAdministration OralMiddle AgedMycophenolic AcidTreatment OutcomeSettore MED/35 - Malattie Cutanee E VenereeEnteric-coated Mycophenolate SodiumHumansPrednisoneDrug Therapy CombinationFemaleTablets Enteric-CoatedGlucocorticoidsImmunosuppressive AgentsPemphigusFollow-Up StudiesInternational journal of dermatology
researchProduct

Impact of switching from mycophenolate mofetil to enteric-coated mycophenolate sodium on gastrointestinal side effects in patients with autoimmune di…

2015

Bernhard Manger,1 Falk Hiepe,2 Matthias Schneider,3 Margitta Worm,4 Peter Wimmer,5 Eva-Maria Paulus,5 Andreas Schwarting6 1University Hospital Erlangen, Med Clinic III Polyclinic, Erlangen, 2Rheumatology, University Hospital Charité, Campus Mitte, Berlin, 3Policlinic of Rheumatology, Heinrich-Heine-Universität, Düsseldorf, 4Department of Dermatology, Venereology and Allergology, University Hospital Charité, Campus Mitte, Berlin, 5Novartis Pharma GmbH, Nürnberg, 6Department of Internal Medicine, Johannes Gutenberg University, Mainz, Germany Background: The purpose of this study was to assess changes in gastrointestinal symptom severity in pati…

medicine.medical_specialtyAbdominal painClinical and Experimental GastroenterologyNauseabusiness.industrymycophenolate mofetilGastroenterologyautoimmune diseaseenteric-coated mycophenolate sodiumpatient-reported outcomeIndigestionhealth-related quality of lifeQuality of lifeRating scaleInternal medicineClinical endpointmedicinePatient-reported outcomemedicine.symptomAdverse effectbusinessOriginal ResearchClinical and Experimental Gastroenterology
researchProduct

Mycophenolate mofetil and enteric-coated mycophenolate sodium in the treatment of pemphigus vulgaris and pemphigus foliaceus.

2014

What is known and objective: Pemphigus is a severe, potentially life-threatening autoimmune blistering disease. The use of corticosteroids has dramatically improved the prognosis and changed its course. However, current morbidity of pemphigus is largely iatrogenic, caused by side effects of the long-term, high-dose corticosteroid therapy that is necessary to sustain disease control. In order to minimize side effects, a range of corticosteroid-sparing immunosuppressive agents have been introduced, including mycophenolate mofetil (MMF) and enteric-coated mycophenolate sodium (EC-MPS). A systematic review was performed to evaluate the effectiveness of MMF and EC-MPS in the treatment of pemphig…

medicine.medical_specialtyEnteric-coated mycophenolate sodium mycophenolate mofetil mycophenolic acid pemphigus foliaceus pemphigus vulgaris therapyDermatologyMycophenolateMycophenolic acidimmune system diseasesmedicineSettore MED/35 - Malattie Cutanee E VenereeHumansEnteric coatedskin and connective tissue diseasesGlucocorticoidsPemphigus foliaceusintegumentary systembusiness.industryPemphigus vulgarisMycophenolate SodiumMycophenolic AcidPrognosismedicine.diseaseDermatologyPemphigusTreatment OutcomeDrug Therapy CombinationDermatologic AgentsbusinessImmunosuppressive AgentsPemphigusmedicine.drugBlistering disease
researchProduct